122 completed, 43 terminated, 26 recruiting, 24 unknown. 238 Phase 3, 27 Phase 2.
Follow Crohn Disease: new trials by email Literature Review of Crohn Disease trials Research Report on Crohn Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease JNJ-78934804, Guselkumab - Crohn Disease | Phase 3 | Recruiting | Janssen Research & Development, LLC | 460 | 2026-05-22 | 2026-11-03 |
| A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Guselkumab, Risankizumab - Crohn Disease | Phase 3 | Recruiting | Janssen Research & Development, LLC | 530 | 2026-04-21 | 2026-11-03 |
| A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease Duvakitug, Placebo - Crohn's Disease | Phase 3 | Recruiting | Sanofi | 751 | 2026-01-22 | 2026-10-21 |
| A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD) Vedolizumab SC, No Intervention - Ulcerative Colitis, Crohn's Disease | Phase 3 | Recruiting | Takeda | 70 | 2025-10-27 | 2026-10-09 |
| Risankizumab for Fibrostenotic Crohn's Disease Treatment Ustekinumab, Risankizumab - Crohn Disease, Crohn Disease and Ulcerative Colitis | Phase 3 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 260 | 2025-10-20 | 2025-09-16 |
| A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease Icotrokinra, Placebo - Crohn Disease | Phase 2 / Phase 3 | Recruiting | Janssen Research & Development, LLC | 1092 | 2025-10-03 | 2026-11-03 |
| An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease Duvakitug, Placebo - Crohn's Disease | Phase 3 | Recruiting | Sanofi | 980 | 2025-10-01 | 2026-10-21 |
| Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight Mirikizumab, Tirzepatide, Placebo - Crohn's Disease, Obesity or Overweight | Phase 3 | Recruiting | Eli Lilly and Company | 290 | 2025-06-26 | 2026-11-04 |
| Phase 3 Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease Human TH-SC01 cell injection, Saline solution - Crohn's Disease | Phase 3 | Recruiting | Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | 228 | 2025-03-20 | 2025-04-13 |
| A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Vedolizumab IV, Vedolizumab SC - Ulcerative Colitis, Crohn's Disease | Phase 3 | Recruiting | Takeda | 70 | 2025-01-22 | 2026-08-03 |
| A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease Vedolizumab, Upadacitinib, Placebo - Crohn's Disease | Phase 3 | Recruiting | Takeda | 396 | 2025-01-02 | 2026-05-27 |
| Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) Tulisokibart, Placebo to tulisokibart - Crohn Disease, Colitis, Ulcerative | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1380 | 2024-11-25 | 2026-11-10 |
| A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants Guselkumab - Crohns Disease, Colitis, Ulcerative | Phase 3 | Recruiting | Janssen Research & Development, LLC | 196 | 2024-10-29 | 2026-11-03 |
| Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease Fluconazole, Placebo, IL-23 Therapy - Crohn's Disease, Inflammatory Bowel Diseases | Phase 3 | Recruiting | Weill Medical College of Cornell University | 120 | 2024-10-04 | 2026-08-20 |
| Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease Upadacitinib - Crohn's Disease | Phase 3 | Active not recruiting | AbbVie | 111 | 2024-08-08 | 2026-10-16 |
| Evaluation of the Efficacy of Local Budesonide Treatment in Children with Crohn's Disease Located in the Esophagus And/or Stomach And/or Duodenum budesonide, omeprazole (proton pump inhibitor) - Crohn Disease (CD) | Phase 2 / Phase 3 | Enrolling by invitation | Medical University of Warsaw | 114 | 2024-07-30 | 2024-12-06 |
| Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous as Induction Therapy in Patients With Active CD or UC CT-P13 - Inflammatory Bowel Diseases | Phase 3 | Unknown | CMC Ambroise Paré | 130 | 2024-07-10 | 2024-07-31 |
| A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) IV Tulisokibart, SC Tulisokibart, IV Placebo - Crohn's Disease | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1200 | 2024-06-05 | 2026-11-16 |
| SAVES-IBD: Safety & Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After IBD Surgery Aspirin 81Mg Ec Tab, Standard of Care - Crohn Disease, Ulcerative Colitis | Phase 3 | Withdrawn | Stefan Holubar MD MS FACS, FASCRS | 2024-06-01 | 2024-04-18 | |
| Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients Guselkumab - Crohn's Disease | Phase 3 | Active not recruiting | Janssen-Cilag Ltd. | 120 | 2024-04-17 | 2026-11-03 |
Showing 20 of 238. Sign in to see all of them.
Inflammatory Bowel Diseases (41) · Colitis, Ulcerative (27) · Anemia (4) · Anemia, Iron-Deficiency (4) · Colitis (4) · Inflammation (4) · Iron Deficiencies (4) · Arthritis, Juvenile (3) · Fistula (3) · Intestinal Diseases (3) · Anemia, Dyserythropoietic, Congenital (2) · Arthritis, Psoriatic (2) · Colonic Neoplasms (2) · Colorectal Neoplasms (2)
Digestive System Diseases (237) · Gastroenteritis (237) · Gastrointestinal Diseases (236) · Intestinal Diseases (235) · Inflammatory Bowel Diseases (197) · Colonic Diseases (35) · Colitis (27) · Pathological Conditions, Signs and Symptoms (13) · Nutritional and Metabolic Diseases (8) · Pathologic Processes (7) · Hematologic Diseases (6) · Hemic and Lymphatic Diseases (6) · Metabolic Diseases (6) · Bone Diseases (5) · Musculoskeletal Diseases (5)
Adalimumab (29) · Infliximab (18) · Certolizumab Pegol (16) · Ustekinumab (13) · Azathioprine (12) · vedolizumab (12) · guselkumab (9) · risankizumab (9) · Mesalamine (8) · Budesonide (6) · mirikizumab (5) · ozanimod (5) · upadacitinib (5) · CCX282-B (4) · ontamalimab (4)
Takeda (15) · AbbVie (14) · Janssen Research & Development, LLC (13) · Abbott (12) · UCB Pharma (11) · Celgene (7) · Centocor, Inc. (5) · Eli Lilly and Company (5) · GlaxoSmithKline (4) · Shire (4) · Sixth Affiliated Hospital, Sun Yat-sen University (4) · Assistance Publique - Hôpitaux de Paris (3) · AstraZeneca (3) · Biogen (3) · Dr. Falk Pharma GmbH (3)
United States (130) · Canada (94) · Belgium (91) · Poland (86) · Germany (85) · France (83) · Italy (79) · Spain (78) · Israel (76) · United Kingdom (71) · Czechia (68) · Netherlands (68) · Australia (62) · Hungary (61) · South Korea (60)
Anne Camez, MD (3) · Christopher James, PA (2)
PMID 37368103, PMID 40357993, PMID 29380251, PMID 36208720, PMID 26893500, PMID 27959607, PMID 29142515, PMID 29409871, PMID 29909019, PMID 30739254, PMID 31279870, PMID 32964215, PMID 34077627, PMID 35435862, PMID 36150926, PMID 37224198, PMID 37391056, PMID 38096402, PMID 38310565, PMID 38492903, PMID 38492904, PMID 38982567, PMID 39054592, PMID 39131711, PMID 39231444, PMID 39485390, PMID 41189093, PMID 41264726, PMID 41763462, PMID 42427284, PMID 16267322, PMID 17634466, PMID 18398081, PMID 19201775, PMID 22325170, PMID 22704916, PMID 25996351, PMID 28420280, PMID 29857145, PMID 29939254, PMID 30054164, PMID 30203005, PMID 30615117, PMID 32445184, PMID 32635680, PMID 34216825, PMID 34546360, PMID 35644154, PMID 38835235, PMID 39326583
2023 (17), 2017 (10), 2016 (6), 2019 (6), 2008 (4), 2014 (4), 2005 (3), 2015 (3), 2018 (3), 2025 (3), 2004 (1), 2009 (1), R01DK132408 (1), R01HD099344 (1)